New Insights into Prostate Cancer Biology

Hematology/Oncology Clinics of North America

Volumn 20, Issue 4, 2006, Pages 773-796

  Balakumaran, Bala S ^a,b   Febbo, Phillip G ^a,b,c  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANDROGEN RECEPTOR; ANTIANDROGEN; BETA CATENIN; DAXX PROTEIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FRIZZLED PROTEIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; MIFEPRISTONE; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 PHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; RETINOBLASTOMA PROTEIN; RNA; SONIC HEDGEHOG PROTEIN; STAT PROTEIN; STEROID RECEPTOR COACTIVATOR 1; WNT1 PROTEIN;

ANDROGEN ABLATION THERAPY; APOPTOSIS; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESEARCH; CANCER RISK; CANCER SURGERY; CANCER SUSCEPTIBILITY; CASTRATION; DNA BINDING; DNA METHYLATION; DNA MODIFICATION; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME REGULATION; GENE AMPLIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC MANIPULATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOME ANALYSIS; GENOMICS; GNETOPHYTA; HOMEOBOX; HORMONE RESISTANCE; HUMAN; METASTASIS; NONHUMAN; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; REVIEW; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; VIRUS ONCOGENE; XENOGRAFT;

GENOMICS; HUMANS; MALE; ONCOGENE PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 33745987949     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.06.005     Document Type: Review

References (141)

1. Huggins C., and Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 29-52
2. Febbo P.G., and Brown M.A. Nuclear receptors in normal prostatic growth and disease. In: Kantoff P.W., Carroll P.R., and D'Amico A.V. (Eds). Prostate cancer: principles and practice (2002), Lippincott Williams & Wilkins, New York 29
3. Taplin M.E., and Balk S.P. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91 (2004) 483
4. Stanbrough M., Leav I., Kwan P.W., et al. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci USA 98 (2001) 10823
5. Berger R., Febbo P.G., Majumder P.K., et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 64 (2004) 8867
6. Cunha G.R., Hayward S.W., Wang Y.Z., et al. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 107 (2003) 1
7. Hayward S.W., Wang Y., Cao M., et al. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 61 (2001) 8135
8. Scher H.I., and Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23 (2005) 8253
9. Bubendorf L., Kononen J., Koivisto P., et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59 (1999) 803
10. Koivisto P., Hyytinen E., Palmberg C., et al. Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am J Pathol 147 (1995) 1608
11. Visakorpi T., Hyytinen E., Koivisto P., et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9 (1995) 401
12. Taplin M.E., Bubley G.J., Ko Y.J., et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59 (1999) 2511
13. Taplin M.E., Bubley G.J., Shuster T.D., et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332 (1995) 1393
14. Krishnan A.V., Zhao X.Y., Swami S., et al. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology 143 (2002) 1889
15. Zhao X.Y., Boyle B., Krishnan A.V., et al. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol 162 (1999) 2192
16. Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (2004) 33
17. Stanbrough M., Bubley G.J., Ross K., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 (2006) 2815
18. Solit D.B., Zheng F.F., Drobnjak M., et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8 (2002) 986
19. Harashima K., Akimoto T., Nonaka T., et al. Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor. Int J Radiat Biol 81 (2005) 63
20. Solit D.B., Scher H.I., and Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 30 (2003) 709
21. Amler L.C., Agus D.B., LeDuc C., et al. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res 60 (2000) 6134
22. Febbo P.G., Lowenberg M., Thorner A.R., et al. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J Urol 173 (2005) 1772
23. Ko Y.J., and Balk S.P. Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers. Curr Pharm Biotechnol 5 (2004) 459
24. Wang Q., Carroll J.S., and Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 19 (2005) 631
25. Chen J.D., and Li H. Coactivation and corepression in transcriptional regulation by steroid/nuclear hormone receptors. Crit Rev Eukaryot Gene Expr 8 (1998) 169
26. Gregory C.W., He B., Johnson R.T., et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61 (2001) 4315
27. Cheng S., Brzostek S., Lee S.R., et al. Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol 16 (2002) 1492
28. Hodgson M.C., Astapova I., Cheng S., et al. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem 280 (2005) 6511
29. Song L.N., and Gelmann E.P. Interaction of beta-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor. J Biol Chem 280 (2005) 37853
30. Craft N., Shostak Y., Carey M., et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5 (1999) 280
31. Hayes S.A., Zarnegar M., Sharma M., et al. SMAD3 represses androgen receptor-mediated transcription. Cancer Res 61 (2001) 2112
32. Gross M., Liu B., Tan J., et al. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene 20 (2001) 3880
33. Gross M., Yang R., Top I., et al. PIASy-mediated repression of the androgen receptor is independent of sumoylation. Oncogene 23 (2004) 3059
34. Lin D.Y., Fang H.I., Ma A.H., et al. Negative modulation of androgen receptor transcriptional activity by Daxx. Mol Cell Biol 24 (2004) 10529
35. Mellinghoff I.K., Vivanco I., Kwon A., et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6 (2004) 517
36. Brinkmann A.O., Jenster G., Kuiper G.G., et al. The human androgen receptor: structure/function relationship in normal and pathological situations. J Steroid Biochem Mol Biol 41 (1992) 361
37. Gioeli D., Black B.E., Gordon V., et al. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol 20 (2006) 503
38. Daaka Y. G proteins in cancer: the prostate cancer paradigm. Sci STKE 216 (2004) re2
39. Salas T.R., Kim J., Vakar-Lopez F., et al. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279 (2004) 19191
40. Huang Z.Q., Li J., Sachs L.M., et al. A role for cofactor-cofactor and cofactor-histone interactions in targeting p300, SWI/SNF and Mediator for transcription. EMBO J 22 (2003) 2146
41. Fu M., Wang C., Zhang X., et al. Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem Pharmacol 68 (2004) 1199
42. Fu M., Rao M., Wang C., et al. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 23 (2003) 8563
43. Kang Z., Janne O.A., and Palvimo J.J. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 18 (2004) 2633
44. Korkmaz C.G., Fronsdal K., Zhang Y., et al. Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation-rescue of transcriptionally compromised mutants. J Endocrinol 182 (2004) 377
45. Cheng J., Wang D., Wang Z., et al. SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol 24 (2004) 6021
46. Poukka H., Karvonen U., Janne O.A., et al. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci USA 97 (2000) 14145
47. Zheng Z., Cai C., Omwancha J., et al. SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells. J Biol Chem 281 (2006) 4002
48. Revankar C.M., Cimino D.F., Sklar L.A., et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307 (2005) 1625
49. Baron S., Manin M., Beaudoin C., et al. Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. J Biol Chem 279 (2004) 14579
50. Nelson W.G., De Marzo A.M., and Isaacs W.B. Prostate cancer. N Engl J Med 349 (2003) 366
51. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57
52. Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22 (2004) 2954
53. Deocampo N.D., Huang H., and Tindall D.J. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol 28 (2003) 145
54. Lin J., Adam R.M., Santiestevan E., et al. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 59 (1999) 2891
55. Wang S., Gao J., Lei Q., et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4 (2003) 209
56. Trotman L.C., Niki M., Dotan Z.A., et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 1 (2003) E59
57. Chen Z., Trotman L.C., Shaffer D., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436 (2005) 725
58. Mayo L.D., Dixon J.E., Durden D.L., et al. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277 (2002) 5484
59. Stambolic V., MacPherson D., Sas D., et al. Regulation of PTEN transcription by p53. Mol Cell 8 (2001) 317
60. Chen W.W., Chan D.C., Donald C., et al. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 3 (2005) 443
61. Neshat M.S., Mellinghoff I.K., Tran C., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98 (2001) 10314
62. Majumder P.K., Yeh J.J., George D.J., et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci USA 100 (2003) 7841
63. Majumder P.K., Febbo P.G., Bikoff R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10 (2004) 594
64. Hara K., Maruki Y., Long X., et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110 (2002) 177
65. Kim D.H., Sarbassov D.D., Ali S.M., et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110 (2002) 163
66. Adhikary S., and Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6 (2005) 635
67. Hemann M.T., Bric A., Teruya-Feldstein J., et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436 (2005) 807
68. Dang C.V., O'Donnell K.A., and Juopperi T. The great MYC escape in tumorigenesis. Cancer Cell 8 (2005) 177
69. Edwards J., Krishna N.S., Witton C.J., et al. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 9 (2003) 5271
70. Gil J., Kerai P., Lleonart M., et al. Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res 65 (2005) 2179
71. Williams K., Fernandez S., Stien X., et al. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate 63 (2005) 369
72. Ellwood-Yen K., Graeber T.G., Wongvipat J., et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4 (2003) 223
73. Amundadottir L.T., Sulem P., Gudmundsson J., et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 38 (2006) 652-658
74. Sciavolino P.J., Abrams E.W., Yang L., et al. Tissue-specific expression of murine Nkx3.1 in the male urogenital system. Dev Dyn 209 (1997) 127
75. He W.W., Sciavolino P.J., Wing J., et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 43 (1997) 69
76. Asatiani E., Huang W.X., Wang A., et al. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res 65 (2005) 1164
77. Abdulkadir S.A., Magee J.A., Peters T.J., et al. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 22 (2002) 1495
78. Kim M.J., Bhatia-Gaur R., Banach-Petrosky W.A., et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 62 (2002) 2999
79. Abate-Shen C., Banach-Petrosky W.A., Sun X., et al. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 63 (2003) 3886
80. Gary B., Azuero R., Mohanty G.S., et al. Interaction of Nkx3.1 and p27kip1 in prostate tumor initiation. Am J Pathol 164 (2004) 1607
81. Korkmaz C.G., Korkmaz K.S., Manola J., et al. Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis. J Urol 172 (2004) 1134
82. Ornstein D.K., Cinquanta M., Weiler S., et al. Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium. J Urol 165 (2001) 1329
83. Chen H., Nandi A.K., Li X., et al. NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res 62 (2002) 338
84. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644
85. Ouyang X., DeWeese T.L., Nelson W.G., et al. Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res 65 (2005) 6773
86. Shen M.M., and Abate-Shen C. Roles of the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Dev Dyn 228 (2003) 767
87. Phillips S.M., Barton C.M., Lee S.J., et al. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 70 (1994) 1252
88. Theodorescu D., Broder S.R., Boyd J.C., et al. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 158 (1997) 131
89. Gingrich J.R., Barrios R.J., Morton R.A., et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 56 (1996) 4096
90. Winter S.F., Cooper A.B., and Greenberg N.M. Models of metastatic prostate cancer: a transgenic perspective. Prostate Cancer Prostatic Dis 6 (2003) 204
91. Maddison L.A., Sutherland B.W., Barrios R.J., et al. Conditional deletion of Rb causes early stage prostate cancer. Cancer Res 64 (2004) 6018
92. Elgavish A., Wood P.A., Pinkert C.A., et al. Transgenic mouse with human mutant p53 expression in the prostate epithelium. Prostate 61 (2004) 26
93. Hahn W.C., Dessain S.K., Brooks M.W., et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 22 (2002) 2111
94. Hill R., Song Y., Cardiff R.D., et al. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123 (2005) 1001
95. Cunha G.R., Hayward S.W., and Wang Y.Z. Role of stroma in carcinogenesis of the prostate. Differentiation 70 (2002) 473
96. Stecca B., Mas C., Ruiz i Altaba A., et al. Interference with HH-GLI signaling inhibits prostate cancer. Trends Mol Med 11 (2005) 199-203
97. Karhadkar S.S., Bova G.S., Abdallah N., et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431 (2004) 707
98. Sheng T., Li C., Zhang X., et al. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer 3 (2004) 29
99. Sanchez P., Hernandez A.M., Stecca B., et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci USA 101 (2004) 12561
100. Burger P.E., Xiong X., Coetzee S., et al. Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proc Natl Acad Sci USA 102 (2005) 7180
101. Lam J.S., and Reiter R.E. Stem cells in prostate and prostate cancer development. Urol Oncol 24 (2006) 131
102. Signoretti S., Pires M.M., Lindauer M., et al. p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci USA 102 (2005) 11355
103. Polakis P. Wnt signaling and cancer. Genes Dev 14 (2000) 1837
104. Yardy G.W., and Brewster S.F. Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis 8 (2005) 119
105. Verras M., and Sun Z. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett 237 (2006) 22-32
106. Sasaki C.Y., Lin H., Morin P.J., et al. Truncation of the extracellular region abrogrates cell contact but retains the growth-suppressive activity of E-cadherin. Cancer Res 60 (2000) 7057
107. De Marzo A.M., Knudsen B., Chan-Tack K., et al. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 53 (1999) 707
108. Zi X., Guo Y., Simoneau A.R., et al. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 65 (2005) 9762
109. Chen G., Shukeir N., Potti A., et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101 (2004) 1345
110. Chesire D.R., Ewing C.M., Gage W.R., et al. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 21 (2002) 2679
111. Chen M.W., Vacherot F., De La Taille A., et al. The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells. Oncogene 21 (2002) 7861
112. de la Taille A., Rubin M.A., Chen M.W., et al. Beta-catenin related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res 9 (2003) 1801-1807
113. Dong J.T., Lamb P.W., Rinker-Schaeffer C.W., et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268 (1995) 884
114. Kim J.H., Kim B., Cai L., et al. Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature 434 (2005) 921
115. Sharma M., Chuang W.W., and Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem 277 (2002) 30935
116. Schaid D.J. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 13 Spec. No. 1 (2004) R103
117. Carpten J., Nupponen N., Isaacs S., et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 30 (2002) 181
118. Casey G., Neville P.J., Plummer S.J., et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 32 (2002) 581
119. Urisman A., Molinaro R.J., Fischer N., et al. Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2 (2006) e25
120. Petros J.A., Baumann A.K., Ruiz-Pesini E., et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA 102 (2005) 719
121. Gomez-Zaera M., Abril J., Gonzalez L., et al. Identification of somatic and germline mitochondrial DNA sequence variants in prostate cancer patients. Mutat Res 595 (2006) 42
122. Parsons J.K., Nelson C.P., Gage W.R., et al. GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue. Prostate 49 (2001) 30
123. Dhanasekaran S.M., Barrette T.R., Ghosh D., et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412 (2001) 822
124. Lapointe J., Li C., Higgins J.P., et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101 (2004) 811
125. Luo J., Duggan D.J., Chen Y., et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 61 (2001) 4683
126. Singh D., Febbo P.G., Ross K., et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1 (2002) 203
127. Welsh J.B., Sapinoso L.M., Su A.I., et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61 (2001) 5974
128. Luo J., Zha S., Gage W.R., et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62 (2002) 2220
129. Rubin M.A., Zhou M., Dhanasekaran S.M., et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287 (2002) 1662
130. Lieberfarb M.E., Lin M., Lechpammer M., et al. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res 63 (2003) 4781
131. Saramaki O.R., Porkka K.P., Vessella R.L., et al. Genetic aberrations in prostate cancer by microarray analysis. Int J Cancer (2006) in press
132. Petricoin III E.F., Ornstein D.K., Paweletz C.P., et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 94 (2002) 1576
133. Wang X., Yu J., Sreekumar A., et al. Autoantibody signatures in prostate cancer. N Engl J Med 353 (2005) 1224
134. Glinsky G.V., Glinskii A.B., Stephenson A.J., et al. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113 (2004) 913
135. Henshall S.M., Afar D.E., Hiller J., et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 63 (2003) 4196
136. Febbo P.G., and Sellers W.R. Use of expression analysis to predict outcome after radical prostatectomy. J Urol 170 (2003) S11
137. Paris P.L., Andaya A., Fridlyand J., et al. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 13 (2004) 1303
138. Seligson D.B., Horvath S., Shi T., et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435 (2005) 1262
139. Varambally S., Dhanasekaran S.M., Zhou M., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 (2002) 624
140. Ramaswamy S., Ross K.N., Lander E.S., et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 33 (2003) 49
141. Varambally S., Yu J., Laxman B., et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8 (2005) 393